These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11574892)

  • 21. In vivo topoisomerase II cleavage sites in the ribosomal DNA of Physarum polycephalum.
    Borde V; Duguet M
    Biochemistry; 1996 May; 35(18):5787-95. PubMed ID: 8639539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
    Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
    Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene regulation and priming by topoisomerase IIα in embryonic stem cells.
    Thakurela S; Garding A; Jung J; Schübeler D; Burger L; Tiwari VK
    Nat Commun; 2013; 4():2478. PubMed ID: 24072229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
    Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
    Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topoisomerase II activity is not involved in the maintenance of active beta-globin chromatin structure in avian reticulocytes.
    Brotherton TW; Zenk DW; Bennett JP; Ginder GD
    Prog Clin Biol Res; 1989; 316B():57-67. PubMed ID: 2559411
    [No Abstract]   [Full Text] [Related]  

  • 26. DNA topoisomerase II as the cellular target of a novel antitumor agent ICRF-193, a bisdioxopiperazine derivative, in Xenopus egg extract.
    Sato M; Ishida R; Ohsumi K; Narita T; Andoh T
    Biochem Biophys Res Commun; 1997 Jun; 235(3):571-5. PubMed ID: 9207198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage.
    Cullinane C; Mazur SJ; Essigmann JM; Phillips DR; Bohr VA
    Biochemistry; 1999 May; 38(19):6204-12. PubMed ID: 10320349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ongoing activity of RNA polymerase II precludes chromatin collapse and DNA fragmentation in Chinese hamster ovary cells.
    Damgaard J; Balslev Y; Møllgaard K; Wassermann K
    Biochem Biophys Res Commun; 1996 Oct; 227(3):677-83. PubMed ID: 8885993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preferential inhibition of the activity of a stimulatory protein of eukaryotic transcription by platinum (II) complexes.
    Matsumoto N; Sekimizu K; Horikoshi M; Ohtsuki M; Kidani Y; Natori S
    Cancer Res; 1983 Sep; 43(9):4338-42. PubMed ID: 6871867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [DNA topoisomerase II alpha: what the devil is it doing in the centrosome?].
    Jacquemin-Sablon A
    Bull Cancer; 2001 Mar; 88(3):233-4. PubMed ID: 11313198
    [No Abstract]   [Full Text] [Related]  

  • 31. Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling.
    Escargueil AE; Plisov SY; Skladanowski A; Borgne A; Meijer L; Gorbsky GJ; Larsen AK
    FASEB J; 2001 Oct; 15(12):2288-90. PubMed ID: 11511510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CBF/NF-Y functions both in nucleosomal disruption and transcription activation of the chromatin-assembled topoisomerase IIalpha promoter. Transcription activation by CBF/NF-Y in chromatin is dependent on the promoter structure.
    Coustry F; Hu Q; de Crombrugghe B; Maity SN
    J Biol Chem; 2001 Nov; 276(44):40621-30. PubMed ID: 11514576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor-stimulated RNA polymerase II transcribes at physiological elongation rates on naked DNA but very poorly on chromatin templates.
    Izban MG; Luse DS
    J Biol Chem; 1992 Jul; 267(19):13647-55. PubMed ID: 1618865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic relocation of chromosomal protein HMG-17 in the nucleus is dependent on transcriptional activity.
    Hock R; Wilde F; Scheer U; Bustin M
    EMBO J; 1998 Dec; 17(23):6992-7001. PubMed ID: 9843505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA topoisomerase II poisons and inhibitors.
    Capranico G; Giaccone G; D'Incalci M
    Cancer Chemother Biol Response Modif; 1999; 18():125-43. PubMed ID: 10800480
    [No Abstract]   [Full Text] [Related]  

  • 36. Nucleolin is required for RNA polymerase I transcription in vivo.
    Rickards B; Flint SJ; Cole MD; LeRoy G
    Mol Cell Biol; 2007 Feb; 27(3):937-48. PubMed ID: 17130237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stimulatory effect of hnRNA on template activity of isolated rat liver chromatin.
    Grabowska M; Brysch B; Jurka J; Chorazky M
    Acta Biochim Pol; 1981; 28(2):135-46. PubMed ID: 7324698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA helicase A interacts with dsDNA and topoisomerase IIalpha.
    Zhou K; Choe KT; Zaidi Z; Wang Q; Mathews MB; Lee CG
    Nucleic Acids Res; 2003 May; 31(9):2253-60. PubMed ID: 12711669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The histone chaperone TAF-I/SET/INHAT is required for transcription in vitro of chromatin templates.
    Gamble MJ; Erdjument-Bromage H; Tempst P; Freedman LP; Fisher RP
    Mol Cell Biol; 2005 Jan; 25(2):797-807. PubMed ID: 15632079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
    Jensen LH; Wessel I; Møller M; Nitiss JL; Sehested M; Jensen PB
    FEBS Lett; 2000 Sep; 480(2-3):201-7. PubMed ID: 11034329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.